Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

Date

2021-05-01

Author

Gumus, Mahmut
Mastey, Vera
Harnett, James
Sezer, Ahmet
Chen, Chieh-I
Cicin, Irfan
Turk, Haci M.
Gogishvili, Miranda
Ozguroglu, Mustafa
Bondarenko, Igor
Kilickap, Saadettin
Ivanescu, Cristina
Naumann, Ulrike
Reaney, Matthew
Konidaris, Gerasimos
Sasane, Medha
Brady, Keri
Li, Siyu
Gullo, Giuseppe
Rietschel, Petra

Advisor

Type

Article

Metadata

Show full item record

Subject

Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Harnett J., et al., -Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021

URI

http://hdl.handle.net/20.500.12645/29674

Collections

• Yeni Yayınlar